In non-small cell lung cancer (NSCLC), TXNRD1 overexpression, driven by NRF2 signaling, has been associated with tumor recurrence, adverse clinical outcomes, and chemoresistance, ultimately enhancing cancer cell survival (81). This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.